Pharmacopeia has identified a pair of new lead compounds for advancement in its alliance with GlaxoSmithKline. The first of the lead compounds forms the basis of a new lead optimization program focused on identifying a treatment for respiratory disease. The other newly identified lead compound is the second from a program in inflammatory pain. As a result of the identification of these new lead compounds, Pharmacopeia will receive milestone payments totaling $1 million from GSK, which is conduct...